Cedars Sinai
Bicuspid Aortic Valves Present Challenges for TAVR
Online decision tool helps IBD patients choose biologic therapy

Researchers have developed a new online tool designed to help patients with inflammatory bowel disease navigate different options for biologic therapy and decide which one would work best for them, according to a study published in the American Journal of Gastroenterology’s “Putting Patients First” special issue.
Sherman Prize winner discusses integration, cooperation in IBD
Debate: Benefits, harms of social media sharing from medical conferences
Sherman Prize honors researchers for their work in Crohn’s, UC
IBD patients with certain clinical, serological, genetic markers more likely to respond poorly to anti-TNFs
Aldoxorubicin improves PFS in patients with relapsed soft tissue sarcoma
VIDEO: Expert discusses breath testing, microbiome link in IBS
CHICAGO — In this exclusive video from Digestive Disease Week, Mark Pimentel, MD, executive director of the Medically Associated Science and Technology program at Cedars Sinai Medical Center in Los Angeles, discusses new developments in understanding the relationship between irritable bowel syndrome and the gut microbiome, and specifically developments in breath testing and emerging microbiome therapeutics shared at the meeting.
IBD patients on social media focus on risks rather than benefits of biologics

A study of social media posts showed patients with inflammatory bowel disease more often share their concerns about the negative side effects of biologics rather than their benefits or costs, leading investigators to conclude that physicians should do more to help patients understand their treatment options.